Login to Your Account

$21M investment raises Mesoblast’s hopes for a better year in 2017

By Cormac Sheridan and Tamra Sami
Staff Writers

Thursday, December 29, 2016

DUBLIN – Chicago Cubs fans excepted, 2016 has been a bad year for many for a whole host of reasons. The travails of the Australian cell therapy developer Mesoblast Ltd. may not have registered broadly, but the firm has had a torrid year.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription